Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

63.82
+1.442.31%
Post-market: 63.51-0.3100-0.49%19:11 EST
Volume:1.99M
Turnover:126.13M
Market Cap:8.94B
PE:43.26
High:64.48
Open:61.13
Low:60.90
Close:62.38
52wk High:76.76
52wk Low:9.57
Shares:140.01M
Float Shares:120.00M
Volume Ratio:0.26
T/O Rate:1.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.48
EPS(LYR):-0.0122
ROE:75.50%
ROA:14.35%
PB:15.72
PE(LYR):-5,234.15

Loading ...

Arrowhead Pharmaceuticals Price Target Maintained With a $100.00/Share by HC Wainwright & Co.

Dow Jones
·
Feb 10

Arrowhead Pharmaceuticals Earnings Call Flags Pivotal 2026

TIPRANKS
·
Feb 08

Arrowhead price target lowered to $78 from $81 at Morgan Stanley

TIPRANKS
·
Feb 06

Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Resmed (RMD) and Bristol-Myers Squibb (BMY)

TIPRANKS
·
Feb 06

U.S. RESEARCH ROUNDUP-Amazon, Estée Lauder, Ralph Lauren

Reuters
·
Feb 06

Arrowhead   Pharmaceuticals  misses Q1 revenue estimates

Reuters
·
Feb 06

Stock Track | Arrowhead Pharmaceuticals Plummets 5.88% Intraday After Missing Q1 Revenue Estimates

Stock Track
·
Feb 06

Arrowhead steigert Umsatz im ersten Quartal 2026 auf 264,03 Mio. USD um mehr als das 100-Fache

Reuters
·
Feb 06

BRIEF-Arrowhead Pharmaceuticals Q1 EPS USD 0.22

Reuters
·
Feb 06

Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results

THOMSON REUTERS
·
Feb 06

BUZZ-ADT rises ahead of S&P SmallCap addition

Reuters
·
Feb 05

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 05

Ciena Set to Join S&P500

MT Newswires Live
·
Feb 05

Arrowhead to replace Ciena in S&P 400 at open on 2/9

TIPRANKS
·
Feb 05

Earning Preview: Arrowhead Pharmaceuticals — revenue is expected to increase, and institutional views tilt positive

Earnings Agent
·
Jan 29

BUZZ-Arrowhead rises as it begins trial of high-cholesterol disorder drug

Reuters
·
Jan 27

Arrowhead Pharmaceuticals Doses First Subject in Clinical Trial of Treatment for Mixed Hyperlipidemia

MT Newswires Live
·
Jan 27

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of Aro-Dimer-Pa – the First Dual Functional Rnai Therapeutic for the Treatment of Mixed Hyperlipidemia

THOMSON REUTERS
·
Jan 27

Arrowhead Pharmaceuticals Inc. Announces Date for Upcoming Annual Stockholders Meeting

Reuters
·
Jan 27

Arrowhead Pharmaceuticals (ARWR) Is Up 5.0% After China Approves Redemplo Commercialisation With Sanofi

Simply Wall St.
·
Jan 25